<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00965874</url>
  </required_header>
  <id_info>
    <org_study_id>LOMAGHI</org_study_id>
    <nct_id>NCT00965874</nct_id>
  </id_info>
  <brief_title>Low Versus High Dose Magnesium Sulfate in the Early Management of Rapid Atrial Fibrillation</brief_title>
  <official_title>Low Versus High Dose Magnesium Sulfate in the Early Management of Rapid Atrial Fibrillation : Randomised Controlled Double Blind Study (LOMAGHI Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Monastir</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Monastir</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective:

      To assess the efficacy and the safety of high (9g) and low dose (4.5g) of MgS in the
      immediate treatment of rapid AF.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Introduction:

      Atrial fibrillation (AF) is a potentially life-threatening cardiac arrhythmia and a frequent
      chief complaint in emergency departments (ED). It is an important concern for a substantial
      proportion of people worldwide. According to the Rotterdam study, the prevalence of AF among
      individuals aged between 55 to 59 years is estimated at 1.1 for 1000 persons/year and 20.7
      for individuals between 80 and 84 years. Given current adult advanced cardiac life support
      (ACLS), the immediate clinical objective in rapid AF is to achieve ventricular rate control.
      Digoxin, beta blockers and calcium channel antagonists are the most widely used agents for
      the emergent treatment of rapid AF. However, their effect is limited because only half of the
      patients will acutely respond to the first intention treatment. Several studies showed that
      the magnesium sulfate (MgS) is beneficial in the control of the rate and the rhythm of AF. In
      addition, hypomagnesemia is present among patients having AF in 20 to 53% of the cases . The
      association of hypomagnesemia and AF is common after a cardiac surgery and the prophylactic
      administration of MgS could be useful in post-operative AF .

      The last meta analysis published in 2007 showed that the MgS is as well efficient in rate
      control (OR = 1.96) as in rhythm control (OR = 1.60) of AF. However most studies included in
      this meta analysis were conducted on limited number of patients (303 patients included for
      rate control outcome analysis and 376 for rhythm control). Consequently we need further
      randomized controlled studies to establish definitively the efficacy and the safety of MgS in
      the early management of rapid AF.

      Objective:

      To assess the efficacy and the safety of high (9g) and low dose (4.5g) of MgS in the
      immediate treatment of rapid AF.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 2009</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HR &lt;90 bpm or 20% reduction from baseline at 24 hours</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Arterial hypotension Bradycardia (HR &lt;45 bpm) Other (chest pain, allergic reaction……)</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">450</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Magnesium Sulfate high dose infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>9 g Magnesium sulfate infusion over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Magnesium Sulfate low dose infusion</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>4.5 magnesium sulfate infusion over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>serum salin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate high dose</intervention_name>
    <description>9 g infusion once during 30 minutes</description>
    <arm_group_label>Magnesium Sulfate high dose infusion</arm_group_label>
    <other_name>Magnesium Sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Sulfate low dose</intervention_name>
    <description>4.5 g magnesium sulfate infusion</description>
    <arm_group_label>Magnesium Sulfate low dose infusion</arm_group_label>
    <other_name>Magnesium Sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebos</intervention_name>
    <description>serum salin</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients presenting to ED with rapid AF (Heart rate &gt;120 bpm).

        Exclusion Criteria:

          -  Unstable hemodynamic state.

          -  Renal insufficiency (creatinemia&gt; 180 µmol/l).

          -  Allergy to MgS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>nouira semir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Monastir</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Monastir</name>
      <address>
        <city>Monastir</city>
        <state>Monstir</state>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Tunisia</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2009</study_first_submitted>
  <study_first_submitted_qc>August 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2009</study_first_posted>
  <last_update_submitted>April 18, 2018</last_update_submitted>
  <last_update_submitted_qc>April 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Monastir</investigator_affiliation>
    <investigator_full_name>Pr. Semir Nouira</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Rapid Atrial Fibrillation</keyword>
  <keyword>Magnesium Sulfate</keyword>
  <keyword>Cardiac arrhythmia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

